Skip to main content
NCBI home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 1995;3(6):222–225. doi: 10.1155/S1064744995000676

Fluconazole (Diflucan®)

Lisa M Hollier 1,✉, Susan M Cox 1
PMCID: PMC2364443  PMID: 18476045

Full Text

The Full Text of this article is available as a PDF (325.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apseloff G., Hilligoss D. M., Gardner M. J., Henry E. B., Inskeep P. B., Gerber N., Lazar J. D. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol. 1991 Apr;31(4):358–361. doi: 10.1002/j.1552-4604.1991.tb03718.x. [DOI] [PubMed] [Google Scholar]
  2. Blum R. A., Wilton J. H., Hilligoss D. M., Gardner M. J., Henry E. B., Harrison N. J., Schentag J. J. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther. 1991 Apr;49(4):420–425. doi: 10.1038/clpt.1991.49. [DOI] [PubMed] [Google Scholar]
  3. De Nollin S., Van Belle H., Goossens F., Thone F., Borgers M. Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrob Agents Chemother. 1977 Mar;11(3):500–513. doi: 10.1128/aac.11.3.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. De Wit S., Weerts D., Goossens H., Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet. 1989 Apr 8;1(8641):746–748. doi: 10.1016/s0140-6736(89)92572-5. [DOI] [PubMed] [Google Scholar]
  5. Debruyne D., Ryckelynck J. P. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet. 1993 Jan;24(1):10–27. doi: 10.2165/00003088-199324010-00002. [DOI] [PubMed] [Google Scholar]
  6. Dismukes W. E., Bradsher R. W., Jr, Cloud G. C., Kauffman C. A., Chapman S. W., George R. B., Stevens D. A., Girard W. M., Saag M. S., Bowles-Patton C. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med. 1992 Nov;93(5):489–497. doi: 10.1016/0002-9343(92)90575-v. [DOI] [PubMed] [Google Scholar]
  7. Dixon D. M., Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy. 1987;33(2):129–140. doi: 10.1159/000238485. [DOI] [PubMed] [Google Scholar]
  8. Foulds G., Brennan D. R., Wajszczuk C., Catanzaro A., Garg D. C., Knopf W., Rinaldi M., Weidler D. J. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol. 1988 Apr;28(4):363–366. doi: 10.1002/j.1552-4604.1988.tb03159.x. [DOI] [PubMed] [Google Scholar]
  9. Foulds G., Wajszczuk C., Weidler D. J., Garg D. J., Gibson P. Steady state parenteral kinetics of fluconazole in man. Ann N Y Acad Sci. 1988;544:427–430. doi: 10.1111/j.1749-6632.1988.tb40440.x. [DOI] [PubMed] [Google Scholar]
  10. Ghannoum M. A., Filler S. G., Ibrahim A. S., Fu Y., Edwards J. E., Jr Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B. Antimicrob Agents Chemother. 1992 Oct;36(10):2239–2244. doi: 10.1128/aac.36.10.2239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Graybill J. R., Sun S. H., Ahrens J. Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858). J Med Vet Mycol. 1986 Apr;24(2):113–119. doi: 10.1080/02681218680000171. [DOI] [PubMed] [Google Scholar]
  12. Haneke E. Fluconazole levels in human epidermis and blister fluid. Br J Dermatol. 1990 Aug;123(2):273–274. doi: 10.1111/j.1365-2133.1990.tb01870.x. [DOI] [PubMed] [Google Scholar]
  13. Houang E. T., Chappatte O., Byrne D., Macrae P. V., Thorpe J. E. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother. 1990 May;34(5):909–910. doi: 10.1128/aac.34.5.909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Inman W., Pearce G., Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol. 1994;46(2):115–118. doi: 10.1007/BF00199872. [DOI] [PubMed] [Google Scholar]
  16. Kobayashi G. S., Travis S. J., Medoff G. Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice. Antimicrob Agents Chemother. 1987 Dec;31(12):2005–2006. doi: 10.1128/aac.31.12.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Konishi H., Morita K., Yamaji A. Effect of fluconazole on theophylline disposition in humans. Eur J Clin Pharmacol. 1994;46(4):309–312. doi: 10.1007/BF00194397. [DOI] [PubMed] [Google Scholar]
  18. Lazar J. D., Wilner K. D. Drug interactions with fluconazole. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S327–S333. doi: 10.1093/clinids/12.supplement_3.s327. [DOI] [PubMed] [Google Scholar]
  19. Osser S., Haglund A., Weström L. Treatment of candidal vaginitis. A prospective randomized investigator-blind multicenter study comparing topically applied econazole with oral fluconazole. Acta Obstet Gynecol Scand. 1991;70(1):73–78. doi: 10.3109/00016349109006182. [DOI] [PubMed] [Google Scholar]
  20. Phillips R. J., Watson S. A., McKay F. F. An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice. Br J Clin Pract. 1990 Jun;44(6):219–222. [PubMed] [Google Scholar]
  21. Powderly W. G., Saag M. S., Cloud G. A., Robinson P., Meyer R. D., Jacobson J. M., Graybill J. R., Sugar A. M., McAuliffe V. J., Follansbee S. E. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. 1992 Mar 19;326(12):793–798. doi: 10.1056/NEJM199203193261203. [DOI] [PubMed] [Google Scholar]
  22. Richardson K., Cooper K., Marriott M. S., Tarbit M. H., Troke P. F., Whittle P. J. Design and evaluation of a systemically active agent, fluconazole. Ann N Y Acad Sci. 1988;544:4–11. doi: 10.1111/j.1749-6632.1988.tb40385.x. [DOI] [PubMed] [Google Scholar]
  23. Shigematsu M. L., Uno J., Arai T. Effect of ketoconazole on isolated mitochondria from Candida albicans. Antimicrob Agents Chemother. 1982 Jun;21(6):919–924. doi: 10.1128/aac.21.6.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Smith E., Franzmann M., Mathiesen L. R. Disseminated histoplasmosis in a Danish patient with AIDS. Scand J Infect Dis. 1989;21(5):573–577. doi: 10.3109/00365548909037887. [DOI] [PubMed] [Google Scholar]
  25. Sobel J. D., Brooker D., Stein G. E., Thomason J. L., Wermeling D. P., Bradley B., Weinstein L. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol. 1995 Apr;172(4 Pt 1):1263–1268. doi: 10.1016/0002-9378(95)91490-0. [DOI] [PubMed] [Google Scholar]
  26. Torregrosa V., De la Torre M., Campistol J. M., Oppenheimer F., Ricart M. J., Vilardell J., Andreu J. Interaction of fluconazole with ciclosporin A. Nephron. 1992;60(1):125–126. doi: 10.1159/000186724. [DOI] [PubMed] [Google Scholar]
  27. Troke P. F., Andrews R. J., Marriott M. S., Richardson K. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother. 1987 May;19(5):663–670. doi: 10.1093/jac/19.5.663. [DOI] [PubMed] [Google Scholar]
  28. Trujillo M. A., Galgiani J. N., Sampliner R. E. Evaluation of hepatic injury arising during fluconazole therapy. Arch Intern Med. 1994 Jan 10;154(1):102–104. [PubMed] [Google Scholar]
  29. Tucker R. M., Williams P. L., Arathoon E. G., Levine B. E., Hartstein A. I., Hanson L. H., Stevens D. A. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother. 1988 Mar;32(3):369–373. doi: 10.1128/aac.32.3.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Uno J., Shigematsu M. L., Arai T. Primary site of action of ketoconazole on Candida albicans. Antimicrob Agents Chemother. 1982 Jun;21(6):912–918. doi: 10.1128/aac.21.6.912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Washton H. Review of fluconazole: a new triazole antifungal agent. Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4 Suppl):229S–233S. doi: 10.1016/0732-8893(89)90141-7. [DOI] [PubMed] [Google Scholar]
  32. van Heusden A. M., Merkus H. M., Euser R., Verhoeff A. A randomized, comparative study of a single oral dose of fluconazole versus a single topical dose of clotrimazole in the treatment of vaginal candidosis among general practitioners and gynaecologists. Eur J Obstet Gynecol Reprod Biol. 1994 Jun 15;55(2):123–127. doi: 10.1016/0028-2243(94)90066-3. [DOI] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES